GlassScriptPhysician profile
Mayur Deepak Mody
NPI 1255751277
$6,381.93
in general payments reported to CMS, 2019-2025
41 companies · $837 in 2025
The $837 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $80.50 · 2022: $787 · 2023: $2,647 · 2024: $2,030 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,353 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,725 · Consulting Fee: $1,200 · Education: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,352.98 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,725.00 |
| Consulting Fee | $1,200.00 |
| Education | $235.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cti Biopharma Corp. | $1,725.00 | 2023 | Vonjo |
| Beigene USA, INC. | $720.67 | 2024-2025 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $607.83 | 2023-2024 | Imfinzi, Lynparza, Enhertu |
| Pfizer INC. | $521.30 | 2021-2025 | |
| Seagen INC. | $302.26 | 2022-2023 | Adcetris |
| Merck Sharp & Dohme LLC | $233.66 | 2023-2025 | Keytruda, Welireg, Keytruda Qlex |
| E.R. Squibb & Sons, L.L.C. | $177.76 | 2022-2025 | Opdivo, Reblozyl |
| Novartis Pharmaceuticals Corporation | $166.89 | 2022-2025 | |
| Daiichi Sankyo INC. | $146.71 | 2021-2025 | Enhertu, Injectafer |
| Celgene Corporation | $119.53 | 2022-2024 | Reblozyl, Opdualag |
| Eisai INC. | $119.37 | 2021-2025 | |
| Gilead Sciences, INC. | $112.40 | 2023-2025 | Trodelvy |
| Exelixis INC. | $109.43 | 2023-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $109.36 | 2022-2024 | Ojjaara |
| Array Biopharma INC | $104.42 | 2023-2025 | Braftovi, Lorbrena, Mektovi |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $88.23 | 2022-2025 | Loqtorzi |
| Abbvie INC. | $79.45 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $77.83 | 2022-2025 | Libtayo |
| Genzyme Corporation | $77.27 | 2023-2025 | |
| Astellas Pharma US INC | $73.77 | 2023-2025 | Padcev |
| Medtronic, INC. | $70.45 | 2023 | Intellis Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $67.58 | 2023-2024 | |
| Genentech USA, INC. | $59.95 | 2022-2024 | Polivy, Lunsumio, Columvi |
| Puma Biotechnology, INC. | $56.51 | 2022-2025 | |
| Stemline Therapeutics INC. | $43.60 | 2023-2024 | Orserdu |
| Jazz Pharmaceuticals INC. | $42.41 | 2022-2023 | |
| Adc Therapeutics America, INC. | $40.50 | 2022-2025 | |
| Amgen INC. | $37.85 | 2022-2024 | Lumakras |
| Foundation Medicine, INC. | $37.30 | 2022-2023 | Foundationone Liquid Cdx |
| Myriad Genetic Laboratories, INC. | $36.72 | 2022-2023 | Myrisk |
| Sumitomo Pharma America, INC. | $25.19 | 2025 | Orgovyx |
| Pharmacyclics LLC, An Abbvie Company | $25.04 | 2022 | |
| Rigel Pharmaceuticals, INC. | $23.96 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Beone Medicines USA, INC. | $21.32 | 2025 | Brukinsa |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Incyte Corporation | $18.34 | 2022 | |
| Servier Pharmaceuticals LLC | $17.76 | 2025 | |
| Janssen Biotech, INC. | $17.21 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.20 | 2025 | Ninlaro |
| Sobi, INC | $16.54 | 2022 | |
| Tersera Therapeutics LLC | $12.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayur Mody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.